SEMA3A and neoplasm: It has been shown that semaphorin 3A (Sema3A) is expressed in ECs during angiogenesis, where it serves as an endogenous inhibitor of angiogenesis that is present in premalignant lesions and lost during tumor progression in human uterine cervical cancer [191].